Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02336815 · ClinicalTrials.gov registry record · Phase 2
Selinexor Treatment of Refractory Myeloma
A Phase 2 study, sponsored by Karyopharm Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 202
- Enrollment target
NCT02336815 is a Phase 2 study that has completed, run by Karyopharm Therapeutics. The registered enrollment target is 202 participants.
The verdict
NCT02336815, a Phase 2 study, has completed, sponsored by Karyopharm Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 202 participants
- Enrollment target
Study Summary
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).
Interventions
- DRUG Selinexor
- DRUG Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2015-05-26 |
| Est. Completion | 2019-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02336815
The ClinicalTrials.gov registry entry for NCT02336815 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Selinexor is the first listed.
NCT02336815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02336815 about?
NCT02336815 is a clinical study titled "Selinexor Treatment of Refractory Myeloma". This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).
What is the current status of trial NCT02336815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2015-05-26. Estimated completion is 2019-07-26.
What interventions are being tested in trial NCT02336815?
The interventions under investigation include: Selinexor (DRUG), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT02336815?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.